Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Dolastatin 11, a Marine Depsipeptide, Arrests Cells at Cytokinesis and Induces Hyperpolymerization of Purified Actin

Ruoli Bai, Pascal Verdier-Pinard, Sanjeev Gangwar, Chad C. Stessman, Kelly J. McClure, Edward A. Sausville, George R. Pettit, Robert B. Bates and Ernest Hamel
Molecular Pharmacology March 2001, 59 (3) 462-469; DOI: https://doi.org/10.1124/mol.59.3.462
Ruoli Bai
1Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland (R.B., P.V.-P., E.H.); 2Department of Chemistry, University of Arizona, Tucson, Arizona (S.G., C.C.S., K.J.M., R.B.B.); 3Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, Maryland (E.A.S.); and 4Department of Chemistry and Biochemistry and Cancer Research Institute, Arizona State University, Tempe, Arizona (G.R.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pascal Verdier-Pinard
1Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland (R.B., P.V.-P., E.H.); 2Department of Chemistry, University of Arizona, Tucson, Arizona (S.G., C.C.S., K.J.M., R.B.B.); 3Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, Maryland (E.A.S.); and 4Department of Chemistry and Biochemistry and Cancer Research Institute, Arizona State University, Tempe, Arizona (G.R.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjeev Gangwar
1Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland (R.B., P.V.-P., E.H.); 2Department of Chemistry, University of Arizona, Tucson, Arizona (S.G., C.C.S., K.J.M., R.B.B.); 3Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, Maryland (E.A.S.); and 4Department of Chemistry and Biochemistry and Cancer Research Institute, Arizona State University, Tempe, Arizona (G.R.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chad C. Stessman
1Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland (R.B., P.V.-P., E.H.); 2Department of Chemistry, University of Arizona, Tucson, Arizona (S.G., C.C.S., K.J.M., R.B.B.); 3Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, Maryland (E.A.S.); and 4Department of Chemistry and Biochemistry and Cancer Research Institute, Arizona State University, Tempe, Arizona (G.R.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly J. McClure
1Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland (R.B., P.V.-P., E.H.); 2Department of Chemistry, University of Arizona, Tucson, Arizona (S.G., C.C.S., K.J.M., R.B.B.); 3Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, Maryland (E.A.S.); and 4Department of Chemistry and Biochemistry and Cancer Research Institute, Arizona State University, Tempe, Arizona (G.R.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward A. Sausville
1Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland (R.B., P.V.-P., E.H.); 2Department of Chemistry, University of Arizona, Tucson, Arizona (S.G., C.C.S., K.J.M., R.B.B.); 3Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, Maryland (E.A.S.); and 4Department of Chemistry and Biochemistry and Cancer Research Institute, Arizona State University, Tempe, Arizona (G.R.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George R. Pettit
1Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland (R.B., P.V.-P., E.H.); 2Department of Chemistry, University of Arizona, Tucson, Arizona (S.G., C.C.S., K.J.M., R.B.B.); 3Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, Maryland (E.A.S.); and 4Department of Chemistry and Biochemistry and Cancer Research Institute, Arizona State University, Tempe, Arizona (G.R.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert B. Bates
1Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland (R.B., P.V.-P., E.H.); 2Department of Chemistry, University of Arizona, Tucson, Arizona (S.G., C.C.S., K.J.M., R.B.B.); 3Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, Maryland (E.A.S.); and 4Department of Chemistry and Biochemistry and Cancer Research Institute, Arizona State University, Tempe, Arizona (G.R.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ernest Hamel
1Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland (R.B., P.V.-P., E.H.); 2Department of Chemistry, University of Arizona, Tucson, Arizona (S.G., C.C.S., K.J.M., R.B.B.); 3Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, Maryland (E.A.S.); and 4Department of Chemistry and Biochemistry and Cancer Research Institute, Arizona State University, Tempe, Arizona (G.R.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The successful synthesis of dolastatin 11, a depsipeptide originally isolated from the mollusk Dolabella auricularia, permitted us to study its effects on cells. The compound arrested cells at cytokinesis by causing a rapid and massive rearrangement of the cellular actin filament network. In a dose-and time-dependent manner, F-actin was rearranged into aggregates, and subsequently the cells displayed dramatic cytoplasmic retraction. The effects of dolastatin 11 were most similar to those of the sponge-derived depsipeptide jasplakinolide, but dolastatin 11 was about 3-fold more cytotoxic than jasplakinolide in the cells studied. Like jasplakinolide, dolastatin 11 induced the hyperassembly of purified actin into filaments of apparently normal morphology. Dolastatin 11 was qualitatively more active than jasplakinolide and, in a quantitative assay we developed, dolastatin 11 was twice as active as jasplakinolide and 4-fold more active than phalloidin. However, in contrast to jasplakinolide and phalloidin, dolastatin 11 did not inhibit the binding of a fluorescent phalloidin derivative to actin polymer nor was it able to displace the phalloidin derivative from polymer. Thus, despite its structural similarity to other agents that induce actin assembly (all are peptides or depsipeptides), dolastatin 11 may interact with actin polymers at a distinct drug binding site.

Footnotes

    • Received August 17, 2000.
    • Accepted November 20, 2000.
  • Send reprint requests to: Dr. E. Hamel, P.O. Box B, Building 469, Room 104, NCI-Frederick, Frederick, MD 21702. E-mail:hamele{at}mail.nih.gov

  • U.S. Government
View Full Text

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 59 (3)
Molecular Pharmacology
Vol. 59, Issue 3
1 Mar 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Dolastatin 11, a Marine Depsipeptide, Arrests Cells at Cytokinesis and Induces Hyperpolymerization of Purified Actin
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
Citation Tools
Research ArticleArticle

Dolastatin 11, a Marine Depsipeptide, Arrests Cells at Cytokinesis and Induces Hyperpolymerization of Purified Actin

Ruoli Bai, Pascal Verdier-Pinard, Sanjeev Gangwar, Chad C. Stessman, Kelly J. McClure, Edward A. Sausville, George R. Pettit, Robert B. Bates and Ernest Hamel
Molecular Pharmacology March 1, 2001, 59 (3) 462-469; DOI: https://doi.org/10.1124/mol.59.3.462

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Dolastatin 11, a Marine Depsipeptide, Arrests Cells at Cytokinesis and Induces Hyperpolymerization of Purified Actin

Ruoli Bai, Pascal Verdier-Pinard, Sanjeev Gangwar, Chad C. Stessman, Kelly J. McClure, Edward A. Sausville, George R. Pettit, Robert B. Bates and Ernest Hamel
Molecular Pharmacology March 1, 2001, 59 (3) 462-469; DOI: https://doi.org/10.1124/mol.59.3.462
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase IIα in Human Leukemia K562 Cells with Acquired Resistance to Etoposide
  • Operational Models for Receptors with Multiple Agonist Sites
  • BODIPY-cyclopamine Binding to Nluc-SMO
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics